Overview

A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body

Status:
Completed
Trial end date:
2021-06-04
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to investigate pharmacokinetics, including dose proportionality, following single intravenous and subcutaneous doses of spesolimab in healthy Chinese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim